Subtype-specific transcription factors are clinically relevant and show distinct therapeutic vulnerabilities in human small cell lung cancer
C. Lang (Vienna, Austria), Z. Megyesfalvi (Budapest, Hungary), B. Szeitz (Budapest, Hungary), A. Lantos (Budapest, Hungary), N. Woldmar (Lund, Sweden), Z. Valko (budapest, Hungary), A. Schwendenwein (Vienna, Austria), F. Oberndorfer (Vienna, Austria), N. Barany (Budapest, Hungary), S. Paku (Budapest, Hungary), V. Laszlo (Vienna, Austria), H. Kiss (Budapest, Hungary), E. Bugyik (Budapest, Hungary), B. Ferencz (Budapest, Hungary), K. Dezso (Budapest, Hungary), Z. Lohinai (Budapest, Hungary), J. Moldvay (Budapest, Hungary), J. Fillinger (Budapest, Hungary), G. Galffy (Budapest, Hungary), C. Rivard (Colorado, United States), F. Hirsch (Colorado, United States), L. Brcic (Graz, Austria), H. Popper (Graz, Austria), I. Kern (Golnik, Slovenia), M. Kovacevic (Golnik, Slovenia), J. Skarda (Olomouc / Ostrava, Czech Republic), M. Mittak (Olomouc / Ostrava, Czech Republic), A. Szasz (Budapest, Hungary), L. Pizzatti (Rio de Janeiro, Brazil), K. Bogos (Budapest, Hungary), M. Hoda (Vienna, Austria), K. Hoetzenecker (Vienna, Austria), G. Marko-Varga (Lund, Sweden), P. Horvatovics (Groningner, Netherlands), F. Renyi-Vamos (Budapest, Hungary), T. Klikovits (Vienna, Austria), K. Schelch (Vienna, Austria), M. Rezeli (Lund, Sweden), B. Döme (Budapest, Hungary)
|     |
IGFBP3 inhibits tumour growth and invasion of H1299 lung cancer cells and leads to improved survival in patients with lung cancer
A. Frille (Leipzig, Germany), H. Kuhn (Leipzig, Germany), M. Petersen (Leipzig, Germany), J. Meyer (Leipzig, Germany), L. Hofmann (Leipzig, Germany), A. Gläser (Leipzig, Germany), S. Taubenheim (Leipzig, Germany), S. Krämer (Leipzig, Germany), J. Broschewitz (Bremen, Germany), M. Von Laffert (Leipzig, Germany), H. Wirtz (Leipzig, Germany)
| |